{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:23:24Z","timestamp":1791401004425,"version":"4.3.3"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.rmed.2025.108498","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:38:00Z","timestamp":1764117480000},"page":"108498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world efficacy of BDP\/FF\/G fixed triple inhalation powder (NEXThaler) therapy in the treatment of moderate to severe COPD patients (RESPONSE study)"],"prefix":"10.1016","volume":"251","author":[{"given":"Vikt\u00f3ria","family":"Dulai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e1s","family":"Keglevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2547-7972","authenticated-orcid":false,"given":"Bal\u00e1zs","family":"S\u00e1nta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5585-3313","authenticated-orcid":false,"given":"Zsolt","family":"Abonyi-T\u00f3th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6891-1044","authenticated-orcid":false,"given":"Ildik\u00f3","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rmed.2025.108498_bib3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1164\/rccm.202406-1254CI","article-title":"Is disease stability an attainable chronic obstructive pulmonary disease treatment goal?","volume":"211","author":"Singh","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.rmed.2025.108498_bib4","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/09031936.00166410","article-title":"What the pulmonary specialist should know about the new inhalation therapies","volume":"37","author":"Laube","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.108498_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000363390","article-title":"New inhaler devices - the good, the bad and the ugly","volume":"88","author":"Lavorini","year":"2014","journal-title":"Respiration"},{"key":"10.1016\/j.rmed.2025.108498_bib6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pupt.2015.02.006","article-title":"Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?","volume":"31","author":"Scichilone","year":"2015","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2025.108498_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2024.107916","article-title":"Particularities of deposition of two ICS-LABA fixed dose combination dry powder aerosol drugs in the airways of COPD patients","volume":"236","author":"Horv\u00e1th","year":"2025","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108498_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106398","article-title":"TRICOP - a real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD","volume":"182","author":"Marth","year":"2021","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108498_bib9","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.2147\/COPD.S382405","article-title":"Effectiveness of extrafine single inhaler triple therapy in chronic obstructive pulmonary disease (COPD) in Germany - the TriOptimize study","volume":"17","author":"Gessner","year":"2022","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108498_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107219","article-title":"Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: a panhellenic prospective non-interventional study - the TRIBUNE study","volume":"212","author":"Porpodis","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108498_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107368","article-title":"Evolving to a single inhaler extrafine LABA\/LAMA\/ICS - Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE)","volume":"218","author":"Brusselle","year":"2023","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108498_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2147\/COPD.S445858","article-title":"TRITRIAL: the impact of fixed triple therapy with beclometasone\/formoterol\/glycopyrronium on health status and adherence in chronic obstructive pulmonary disease in an Italian context of real life","volume":"19","author":"Richeldi","year":"2024","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108498_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17534666241263439","article-title":"Extrafine single inhaler triple therapy effectiveness in COPD patients previously treated with multiple-inhaler triple therapy: the TRIWIN study","volume":"18","author":"Steiropoulos","year":"2024","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.rmed.2025.108498_bib14","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.2147\/COPD.S474354","article-title":"The real-world efficacy of fixed triple inhalation therapy in the treatment of moderate COPD patients (RATIONALE study)","volume":"19","author":"S\u00fcdi","year":"2024","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108498_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/COPD.S291030","article-title":"Comparison of dry-powder inhaler and pressurized metered-dose inhaler formulations of extrafine beclomethasone dipropionate\/formoterol fumarate\/glycopyrronium in patients with COPD: the TRI-D randomized controlled trial","volume":"16","author":"Beeh","year":"2021","journal-title":"Int. J. Chronic Obstr. Pulm. Dis."},{"issue":"1","key":"10.1016\/j.rmed.2025.108498_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108498_bib17","series-title":"National Medical Professional Board: Professional Medical Guideline for the Diagnosis, Management, and Care of Chronic Obstructive Pulmonary Disease (COPD)","year":"2024"},{"issue":"2","key":"10.1016\/j.rmed.2025.108498_bib18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1089\/jamp.2015.1212","article-title":"Validation of the \u2018Test of the Adherence to Inhalers\u2019 (TAI) for asthma and COPD patients","volume":"29","author":"Plaza","year":"2016","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"3","key":"10.1016\/j.rmed.2025.108498_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S2213-2600(14)70001-3","article-title":"Minimum clinically important difference for the COPD assessment test: a prospective analysis","volume":"2","author":"Kon","year":"2014","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.108498_bib20","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4187\/respcare.03272","article-title":"Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD","volume":"60","author":"Zanini","year":"2015","journal-title":"Respir. Care"},{"issue":"1","key":"10.1016\/j.rmed.2025.108498_bib21","first-page":"111","article-title":"Minimal clinically important differences in COPD lung function","volume":"2","author":"Donohue","year":"2005","journal-title":"COPD J. Chronic Obstr. Pulm. Dis."},{"key":"10.1016\/j.rmed.2025.108498_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12931-020-01387-z","article-title":"Measuring disease activity in COPD: is clinically important deterioration the answer?","volume":"21","author":"Singh","year":"2020","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.rmed.2025.108498_bib23","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108498_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107054","article-title":"Clinically important deterioration: a composite tool for managing patients with COPD","volume":"205","author":"Cazzola","year":"2022","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2025.108498_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12931-018-0928-3","article-title":"Long-term outcomes following first short-term clinically important deterioration in COPD","volume":"19","author":"Naya","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2025.108498_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12931-020-01431-y","article-title":"Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial","volume":"21","author":"Rabe","year":"2020","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2025.108498_bib27","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1183\/23120541.00663-2020","article-title":"Prognostic value of clinically important deterioration in COPD: IMPACT trial analysis","volume":"7","author":"Han","year":"2021","journal-title":"ERJ Open Res"},{"issue":"2","key":"10.1016\/j.rmed.2025.108498_bib28","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01603-2024","article-title":"GOLD science committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD","volume":"65","author":"Singh","year":"2025","journal-title":"Eur. Respir. J."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112500561X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095461112500561X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:30:18Z","timestamp":1777595418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095461112500561X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"alternative-id":["S095461112500561X"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108498","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy of BDP\/FF\/G fixed triple inhalation powder (NEXThaler) therapy in the treatment of moderate to severe COPD patients (RESPONSE study)","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108498","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Chiesi Hungary Kft, Budapest, Hungary. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108498"}}